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Abstract: The significant increase in worldwide morbidity and mortality from non-communicable
diseases (NCDs) indicates that the efficacy of existing strategies addressing this crisis may need
improvement. Early identification of the metabolic irregularities associated with the disease process
may be a key to developing early intervention strategies. Unhealthy lifestyle behaviours are well
established drivers of the development of several NCDs, but the impact of such behaviours on health
can vary considerably between individuals. How can it be determined if an individual’s unique
set of lifestyle behaviours is producing disease? Accumulating evidence suggests that lifestyle-
associated activation of oxidative and inflammatory processes is primary driver of the cell and tissue
damage which underpins the development of NCDs. However, the benefit of monitoring subclinical
inflammation and oxidative activity has not yet been established. After reviewing relevant studies
in this context, we suggest that quantification of oxidative stress and inflammatory biomarkers
during the disease-free prodromal stage of NCD development may have clinical relevance as a
timely indicator of the presence of subclinical metabolic changes, in the individual, portending the
development of disease. Monitoring markers of oxidative and inflammatory activity may therefore
enable earlier and more efficient strategies to both prevent NCD development and/or monitor the
effectiveness of treatment.
Keywords: oxidative stress; inflammation; biomarkers; non-communicable disease; lifestyle; preven-
tion; clinical application
1. Introduction
Many benefits have arisen from recent advances in modern technology especially
in the field of medical sciences, enhancing the effectiveness of numerous disease treat-
ments with the consequent improvement in both quality of life and extension in lifespan.
However, living in modern societies has proven to be a double-edged sword, with several
elements of the popular Western lifestyle actually contributing to the development of
age-related chronic diseases, in particular the non-communicable diseases (NCDs) such as
cardiovascular diseases, diabetes, neurodegenerative dementia and cancer [1–3]. While the
lifespan of an individual suffering from any of these diseases may be extended through the
application of an efficient disease management strategy [4], the cumulative effects of unad-
dressed poor lifestyle choices will promote a state of chronic morbidity and make them
more vulnerable to ongoing development of degenerative changes and further NCDs [5,6].
NCDs are the leading causes of morbidity and mortality worldwide. Of the global
reported deaths of 56.4 million in 2015, 70%, or 39.5 million, were due to NCDs including
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14 million people who died too young before the age of 70 [7]. The annual mortality from
NCDs is projected to increase to 55 million throughout the world by the year 2030 [8].
This is a costly outcome in terms of both personal morbidity and financial outlay as it is
estimated that NCDs alone will drain over USD 60 trillion from the global economy from
2011 to 2030 [9].
The prevention of NCDs is a global challenge assigned a high priority by the World
Health Organisation (WHO, Geneva, Switzerland) [8]. NCDs generally have a long prodro-
mal stage often taking many years to develop. As a result, the potential for developing an
NCD increases as the population ages. This rise in disease morbidity linked to the ageing
population poses important challenges to health care systems globally [10]. Therefore, an
effective early preventive strategy is an ideal approach to slow or even halt lifestyle-linked
degenerative processes. Application of such a strategy in a healthcare model that places
emphasis on disease prevention, rather than just disease management, appears necessary
if the burgeoning NCD problem is to be averted [8]. The benefits of implementing a
successful preventive health strategy are immense as it has been estimated that around
80% of type 2 diabetes, 80% of premature heart disease and stroke, and 40% of cancers are
preventable [11]. While the importance of prevention has been highlighted throughout
the literature for many years, integration of a successful preventive strategy for NCDs in
modern health care systems is still not apparent. Although successful in controlling many
of the world’s infectious diseases, the WHO is still searching for an effective way to control
runaway NCDs [8].
As mentioned, NCDs are diseases of generally slow progression with clinical symp-
toms only becoming apparent after considerable cellular damage has occurred in target
tissues. Research now supports the argument that this damage is largely influenced by
biochemical changes associated with a redox imbalance producing a state of “chronic ox-
idative stress” often accompanied or linked to inflammation [12–14]. Oxidative stress has
been identified as a critical step in the initiation and the development of the pathophysio-
logical changes associated with several NCDs [15,16]. Elevated intracellular/plasma levels
of free radicals (molecules with an unpaired valence electron), such as reactive oxygen
species (ROS), can cause severe damage to cellular structures including lipids, proteins
and DNA molecules, disrupting their functions and leading to fundamental damage to the
entire cell [16,17]. Chronic exposure to these oxidative processes creates a subclinical state
of progressive cell damage which accumulates over time. This damage facilitates tissue
remodelling (e.g., to vascular endothelium in CVD) and eventually results in selective
system failures and the dysfunctional state known as disease [14,16,18,19]. Therefore, mea-
surement of biochemical markers associated with oxidative stress and inflammation may
be useful in identifying an individual’s early biochemical shift toward disease, especially
in the initial prodromal stage. The possibility of early (preclinical) detection, afforded by
use of oxidative stress/inflammatory biomarkers, may also enable a more individualised
and sensitive profiling compared to conventional population-based risk assessment tools
that currently rely on downstream biomarkers [20,21].
In this paper, we review the available literature evidence on the importance of lifestyle-
induced oxidative stress and inflammation in the development of NCDs and suggest that
early correction of redox imbalances may be useful in arresting NCD development.
2. Lifestyle Links to NCDs
Unhealthy lifestyle behaviours are widely accepted as primary initiators of the disease
processes through which NCDs develop [1,3,22]. Even though genetic factors have been
shown to play a role, their contribution to NCDs has been estimated to be less than 10% [23].
Therefore, modifiable lifestyle behaviours are especially relevant as they are more amenable
to intervention [11,24,25]. Epidemiological studies clearly identify lifestyle as a primary risk
factor for the development of NCDs [1,11,26,27]. In one large cohort study, after a 20 year
follow up, it was shown that unhealthy lifestyle behaviours including physical inactivity,
alcohol intake, cigarette smoking and low intake of fruits and vegetables were associated
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with increased mortality risk of cardiovascular disease (CVD) and cancer [1]. Furthermore,
in the European Prospective Investigation into Cancer and Nutrition, after a 7-year follow
up, it was shown that practicing healthy lifestyle behaviours including performing physical
activity, adhering to healthy dietary principles, not smoking, and having a body mass index
(BMI) lower than 30, for 7 years was associated with 78% lower risk of developing a chronic
disease (93% lower risk of diabetes, 81% lower risk of myocardial infarction, 50% lower risk
of stroke, and 36% lower risk of cancer) [11]. Lifestyle behaviours are strongly linked to
the development of NCDs, and as also suggested by others [28–30] a better understanding
of the possible biochemical mechanisms through which these behaviours influence the
disease progression will be helpful in informing effective preventive strategies.
3. Risk Scores and Lifestyle Behaviours
It has become increasingly apparent however that the interaction between lifestyle
and the body’s biochemistry is multifaceted requiring complex modelling [22,31–33]. Un-
healthy lifestyle behaviours are well known to cause metabolic changes in plasma levels of
lipids and fasting glucose [33,34]. This has led many to develop various population-based
risk scores composed of these biomarkers to identify groups at risk of NCDs and also to
monitor the efficacy of any preventive approach [20,35–39]. For example, a number of risk
scores are available for the prediction of coronary heart disease such as the Framingham
risk score (FRS) [20,21], World Health Organization/International Society of Hypertension
(WHO/ISH) risk prediction charts [38], American College of Cardiology/American Heart
Association (ACC/AHA) pooled cohort equations [36], the third Joint British Societies’ risk
calculator (RiskJBS) [37], and the Systematic Coronary Risk Evaluation (SCORE) [39]. While
these are validated and widely used tools for the prediction of coronary heart disease, stud-
ies suggest that they tend to underestimate an individual’s actual risk, thereby potentially
delaying initiation of an appropriate intervention such as lifestyle modification [35,40–48].
In regard to the assessment of total cardiovascular (CVD) risk at the population level,
it has been shown that WHO/ISH charts underestimate the risk of Asian populations
with high total CVD risk [44]. Furthermore, the value of FRS in identifying disease risk
has been reported to be less clear in patients with concomitant inflammatory diseases,
such as systemic lupus erythematosus (SLE) [45] and psoriatic arthritis [46], patients with
diabetes [35], breast cancer [47] and metabolic syndrome [48]. While these diseases are
associated with increased risk for premature cardiovascular disease, persons with these
co-morbidities are estimated to have a low risk according to the FRS calculations. In addi-
tion, based on SCORE charts, younger individuals will always be categorised in the low
risk category, even when all constituent risk factor levels are very unfavourable, and no
combination of risk factors will place a 40-year old individual in the high risk category [39].
Thus, other risk biomarkers not currently included in these risk score calculations appear
necessary to more accurately predict actual individual risk. Current risk score calculations
include numerous risk factors such as age, gender, markers of dyslipidaemia, blood pres-
sure, body-mass index (BMI), and history of diabetes and smoking [20,35–39]. However,
these conventional risk factors cannot account for all cases of CVD [35,40–48]. This is, at
least partially, due to the fact that the traditional biomarkers such as total cholesterol (TC)
and low density lipoprotein cholesterol (LDL-C) are not primary initiators of the disease
process, but rather mediators of downstream pathology [49]. This suggests that other,
currently less conventional biomarkers, that are more upstream of the primary damage
process, need to be included in the risk score calculations in order to improve the risk
estimation potency of a probable NCD at the individual level.
4. Oxidative Stress Is Upstream of Conventional NCD Biomarkers
There has been a growing appreciation in the literature of how non-conventional
metabolic, oxidative stress and inflammatory biomarkers are more direct indicators of
NCD pathologies than conventional biomarkers alone. For example, progression to type 1
diabetes has been associated with the downregulation of amino acid metabolites, sugar
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derivatives and fatty acids [29]. Several studies have also identified the critical role of oxida-
tive and inflammatory processes in all phases of coronary artery disease, from foam cell for-
mation to plaque rupture and thrombosis [50–53]. The concept originated from an in vitro
observation that showed oxidised LDL-C but not native LDL-C, could increase the motility
of monocytes via chemotactic activity [54]. The recruitment of monocytes/macrophages to
the damage site through enhanced chemotactic activity is a critical step in the initiation and
progression of the damage to the endothelial cells in the arteries. Oxidised LDL, taken up
by the macrophage scavenger system, if present in excess will transform the macrophages
into a non-functional foam cell which subsequently forms part of the maturing plaque in
the developing atherosclerotic lesion [19]. It also triggers inflammatory processes which
further exacerbate an oxidative environment [55] (Figure 1).
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Figure 1. The interplay between oxidative stress and inflammatory processes (i.e., NFκB and cytokine
activity) in the development of endothelial cell damage and apoptosis. ROS: reactive oxygen species;
Ox-LDL-C: oxidised low density lipoprotein cholesterol; AP-1: activator protein-1; NF-κB: nuclear
factor-kappa B; TNF-α: tumour necrosis fact r- α; IL-1β: interleukin-1β.
In this context, studies in otherwise healthy individuals have shown significant associ-
ations between oxidative stress biomarkers including F2-isoprostanes, malondialdehyde
(MDA), 8- hydroxy deoxyguanosine (8-OHdG), oxidised disulphide form of cystine (CySS),
and the ratio of glutathione (GSH) to its oxidised disulphide form (GSSG), and subclinical
indicators of CVD development such as carotid artery intima-media thickness (CIMT) and
flow-mediated vasodilation (FMD), even after controlling for the conventional CVD risk
markers, such as LDL-C, and FRS [18,56].
In addition, independent and strong correlations have been reported between the
lipid peroxidation biomarkers hydroxy-eicosatetraenoic acids (HETEs) and F2-isoprostanes
and angiographic evidence of CVD, even after adjustment for FRS. The inclusion of these
biomarkers into a multivariate prediction model that also included the FRS has been shown
to significantly improve the prediction of coronary heart disease [57].
In regard to inflammatory biomarkers, the independent association between plasma
levels of inflammatory biomarkers, C-reactive protein (CRP) and interleukin (IL)-6, and
CVD in multivariable analyses including conventional CVD risk factors have previously
been shown [58]. Importantly, it has been reported that plasma CRP levels can help to
estimate the risk of initial cardiovascular events and even improve CVD risk classification
in individuals with intermediate risk [59,60]. Therefore, the measurement of oxidative
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stress and inflammatory biomarkers as part of routine assessment appears to have clin-
ical relevance by increasing the sensitivity of current risk scores and providing an early
indication of the presence of a (subclinical) disease process.
Importantly, the part played by oxidative stress in disease development is consistent
with the oxidative stress theory of ageing which posits that the accumulation of unre-
paired oxidative damage at the cellular level is a primary player in the development of
the aging phenotype [61]. In support of this concept, a number of recent studies from our
laboratory [62,63] and others [64] have confirmed an increased level of oxidative damage
biomarkers in aged tissues. Thus, the association between ageing and increased incidence
of NCDs is at least partly explained by a subclinical increase in oxidative and inflammatory
potential and changes in related biomarkers which underpin and/or exacerbate develop-
ment of several NCDs [14]. However, what is the relationship between oxidative stress
and inflammation?
5. Association between Oxidative Stress and Inflammation
Inflammation is the body’s nonspecific and immediate response by the innate im-
mune system that is initiated in an acute phase response to environmental challenges
such as pathogens and physical or chemical injuries including free radical attack [65,66].
Indeed, increased free radical generation and a state of oxidative stress and inflamma-
tion are closely interrelated. Oxidative stress can cause the damage to tissue that can
trigger an inflammatory response, which in turn, can be a direct inducer of oxidative
stress [53,66]. In this context, oxidative stress has been shown to cause the activation of
redox-sensitive transcription factors, activator protein-1 (AP-1) and nuclear factor-kappa
B (NF-κB) [67]. These factors can induce inflammatory processes and activate the innate
immune system with the subsequent recruitment and the accumulation of inflammatory
cells such as macrophages, leukocytes and neutrophils to the damage site [68,69]. These
inflammatory cells can then produce metabolites of soluble mediators such as arachidonic
acid, chemokines and pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6 and tu-
mour necrosis factor (TNF)-α [70,71]. Elevated levels of these pro-inflammatory cytokines
can result in hepatic production and secretion of acute-phase proteins such as C-reactive
protein (CRP) and also can further recruit inflammatory cells to the damage site [72,73].
Importantly, the generation of oxygen and/or nitrogen free radicals is a characteristic
property of activated immune cells to eliminate pathogens or other stimuli. In other words,
the production of free radicals is the primary damaging agents while the cytokines and
acute phase proteins produced are essentially signalling molecules.
It is important to note that cytokines themselves do not cause direct cellular dam-
age. Indeed, chronic inflammation exerts its cellular side effects largely through excessive
generation of free radicals and depletion of antioxidants [14,66,74]. Hence, the accumu-
lation of activated immune cells at the damage site accelerates the generation of free
radicals and ROS which further promote the ongoing oxidative stress. Therefore, ox-
idative stress triggers an inflammatory response, which can in turn amplify oxidative
stress [53,66] (Figure 1).
6. What Is Redox Imbalance and How Does It Relate to Oxidative Stress?
After the discovery of the oxidation of organic molecules by hydrogen peroxide in
the presence of Fe++ by Fenton in 1894 [75], a series of investigations began in this area
which later became known as oxidative stress. The generation of reactive oxidative species
(ROS), the main players in oxidative reactions, is a normal consequence of all forms of
aerobic life. In mammals, about 95% of inspired oxygen (O2) is successfully reduced to CO2
and H2O, without the formation of toxic radicals. However, the remaining 5%, proceeds
through univalent reduction, producing reactive oxygen species which include superoxide
(O2−) radicals, hydroxyl radical (OH−), hydrogen peroxide (H2O2) and the peroxynitrite
(OONO−) radical [76]. The major sources of ROS production is mitochondrion [77], peroxi-
somal oxidase [78], xanthine oxidase [79], nicotinamide adenine dinucleotide phosphate
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(NADPH) oxidase [80] and cytochrome P450 enzymes [81]. The generation of ROS is
also the major way the immune system uses to attack and kill pathogens and digest cell
debris [53,66,82]. Inflammatory cells such as macrophages and neutrophils contain the
NADPH oxidase system that, when activated, produces large amounts of superoxide and
other damaging radical species that in the case of chronic inflammation can eventually lead
to pervasive collateral cellular damage. Thus, free radical damage is the primary driver of
cellular damage resulting from inflammatory activity [53,66,82,83].
Importantly, some free radical species also play a role as second messengers in con-
trolling significant cellular functions such as the production of chemical mediators, cellular
division and migration [67]. However, as free radicals with at least one unpaired electron in
their atomic structure, they can be harmful at supra physiological concentrations [], and are
counterbalanced by a complex antioxidant defence system comprising enzymatic (e.g., su-
peroxide dismutase, glutathione peroxidise, glutathione reductase, and catalase) and
non-enzymatic sources (e.g., dietary vitamins and phytochemicals, and glutathione) [13].
In all living cells a delicate balance exists between the generation, and the elimination
of ROS by the endogenous antioxidant defence system. This is referred to commonly as the
redox balance. Generally, overproduction of ROS or a defect in the ability of the endogenous
antioxidant defence system to potentially detoxify these reactive substances or to repair
the resulting damage, can lead to a redox imbalance [84]. Redox imbalance contributes
significantly to the development of widespread cellular oxidation. This situation has
been defined as oxidative stress (a state of redox imbalance), which as mentioned can
eventually result in cell damage and death, with the consequent tissue alterations linked to
the development of NCDs [14,16].
7. The Link between Lifestyle Behaviours, Oxidative Stress and Inflammation
As discussed above, a persuasive case is emerging for a pivotal role of oxidative
damage and inflammation in the remodelling of tissue into its diseased phenotype at
the biochemical and cellular levels [14,16,18,19]. Therefore, the assessment of oxidative
and inflammatory biomarkers may improve disease stratification [57]. As previously
mentioned, robust associations between the development of NCDs and unhealthy lifestyle
behaviours have been known for some time [1,3,22]. Therefore, it is plausible that these
two causal factors are interlinked. Indeed, there is a growing body of evidence showing
that various lifestyle behaviours can induce a state of oxidative stress and inflammation
which eventually leads to chronic NCDs [32,85,86] (Figure 2). In the following section,
we provide evidence on how specific modifiable lifestyle behaviours have been linked to
oxidative stress and inflammatory activity.
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7.1. Adiposity and Total and Regio al Body F t
A positive energy balance, due to an imbalance betwee food (energy) intake and
energy exp nditure, can increase total body fat content, and visc ral adip se tissue (VAT)
fat mass, a key indicator of central obe ity [87,88]. Total body fat a VAT have been
reported to be p sitively associated with oxidative and inflammato y processes in several
studies [89–91]. Indeed, ROS generation from NADPH oxidase ctivity has be n detected in
adipose tissue, and has been show to progressively increase in aged adipose tissue [89,90].
There is also evidence that hypertrophic a i ocytes can cause a state of local hypoxia due to
their increased oxygen consumption [92]. Local hypoxia can increase the levels of total ROS
and superoxide in particular, and decrease levels of key antioxidant enzymes, superoxide
dismutase (SOD1 and SOD3) and catalase in adipocytes [90]. Furthermore, hypoxia has
been shown to trigger the up-regulation of hypoxic-inducible factor (HIF) which has been
linked to mitochondrial dysfunction [93] and activation of NF-κB with the subsequent
production of inflammatory cytokines [94]. Another contributor to adipocyte-induced
oxidative stress has been suggested to be alterations in gut microbiota that are accompanied
by enhanced production of gut bacterial metabolite deoxycholic acid (DCA) [95]. DCA is
known to damage DNA molecule through generation of ROS [96]. Visceral fat adipocytes
can also significantly increase levels of plasma inflammatory biomarkers such as CRP [97],
TNF-α [98] and IL-6 [99], either directly by releasing high amounts of these cytokines
or indirectly by producing the inflammatory adipokines, leptin and resistin [91]. These
inflammatory cytokines play a pivotal role in reducing insulin sensitivity and developing
insulin resistant [100]. The persistent hyperglycaemia, secondary to insulin resistance, can
further exacerbate the existing redox imbalance by inducing oxidative stress and contribute
to beta cell destruction in type 2 diabetes [101].
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7.2. Nutritional Behaviours
7.2.1. Energy Intake
In addition to the mentioned indirect effects of high energy intake in promoting a state
of oxidative stress and inflammation via increasing body weight and total body fat [89–91],
energy intake can be directly involved in producing a state of oxidative stress and inflam-
mation [102–106]. Boden et al., reported that feeding healthy men with a high calorie
diet (6000 kcal/day) for one week can produce a rapid onset of systemic oxidative stress
detected by increased lipid peroxidation biomarker 8-iso-PGF2α and also ROS-mediated
protein oxidation and carbonylation [102]. Furthermore, our own research has reported
that ingestion of energy-dense phytonutrient-reduced foods including cream, ice cream or
sugar can increase plasma lipid peroxidation and reduce plasma total antioxidant capacity
(TAC) 2–4 h after ingestion of these foods [107]. In another study, a 25% calorie restriction
for 28 days in obese subjects was reported to reduce the lipid peroxidation biomarker
F2- isoprostane [106]. Furthermore, long term calorie limitation studies on healthy hu-
man subjects have shown that fasting can reduce oxidative damage to DNA and decrease
plasma concentrations of thiobarbituric acid-reactive species (TBARS), carbonylated pro-
teins, otyrosine, and m-tyrosine, all indicators of oxidative damage to lipids, proteins and
amino acids, respectively [104,105]. There are also reports on the effects of short-term
calorie limitation (48 h) on reducing ROS generation by leucocytes [103]. Chronic calorie
restriction can attenuate the age-associated increase in inflammatory IL-6 production by
peripheral mononuclear cells [108] and also reduce plasma inflammatory CRP levels [109].
Several animal and human studies have also suggested the involvement of energy intake
and calorie restriction (10–50% below usual ad libitum intakes) in delaying ageing and
extending lifespan [110]. As a basis for these observations, it has been suggested that calorie
restriction can affect longevity-linked transcripts along the insulin-like growth factor 1
(IGF-1)/insulin/FOXO pathway [111]. However, the exact mechanism responsible for
these observations is yet to be fully understood. Furthermore, it is still not clear whether
these effects are due to a simple reduction in energy intake or the associated reduction in
specific dietary components such as protein [112,113].
7.2.2. Protein Intake
Notwithstanding recommendations for an adequate intake of dietary proteins for the
stimulation of muscle protein synthesis and/or suppression of protein breakdown [114],
studies linking high intakes of proteins with ageing are emerging [115–117]. It has been
suggested that protein restriction (40–85% of standard chow) can increase maximum
lifespan by about 20% in rodents [115]. In humans, high protein intake (more than 20%
of calories) has been associated with a 75% increase in overall mortality [117]. While
suggested mechanisms include effects on ageing-associated molecules such as rapamycin
(mTOR) [118], fibroblast growth factor 21 (FGF21), insulin [119], and insulin like growth
factor 1 (IGF-1) [117], the mechanisms linking protein restriction to ageing are yet to be
fully understood.
It has also been shown that protein restriction can independently reduce mitochondrial
ROS generation, mitochondrial DNA oxidative damage biomarker 8-OHdG [120] and
liver lipid peroxidation [121]. There are also reports that an increased protein intake can
reduce the activity of the antioxidant enzyme superoxide dismutase in liver [121]. Protein
intake and the metabolites of protein catabolism have also been shown to be negatively
associated with the ageing-linked biomolecule, Nicotinamide adenine dinucleotide (NAD+),
in a disease-free cohort [122]. Supplementation of the diet with specific amino acids
(e.g., methionine) has also been shown to increase plasma lipid peroxidation biomarkers of
hydroperoxides [123] and TBARS [124], and reduce tissue vitamin E levels [123].
7.2.3. Processed Meat
Several studies suggest that the source of protein can be as important as the amount
of protein in the diet in ageing, development of NCDs and promoting a state of oxidative
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stress [117,125,126]. In this context, it has been reported that high consumption of animal
proteins specifically those derived from red meat was positively associated with plasma
lipid peroxidation biomarker TBARs and was negatively associated with plasma antioxi-
dant capacity [126]. Red meat is a complex medium containing high amounts of saturated
fat, trans fat and heme-iron and its effect on promoting oxidative stress may be attributed,
at least in part, to the cumulative pro-oxidant properties of these components [126,127].
Furthermore, cooking meat using high-temperature methods such as frying can produce
highly pro-oxidant products such as advanced glycation end products (AGE), heterocyclic
amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs) [128–131]. Red meat is also
a rich source of choline and L-carnitine, nutrients which can be metabolised to trimethy-
lamine (TMA) by gut microbiota in colon, and then oxidised to trimethlyamine-N-oxide
(TMAO) in the liver [132]. An elevated TMAO level as a result of high red meat intake has
been shown to promote oxidative stress and vascular inflammation [133].
7.2.4. Polyunsaturated Fatty Acids
Polyunsaturated fatty acids (PUFAs) are fatty acids that contain more than one double
bond in their structure. According to the position of their first double bond from the methyl
end of the carbon chain, PUFAs can be categorised into omega-3 FAs with the first double
bond at the third carbon atom (e.g., alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA)), and omega-6 FAs with the first double bond at the
sixth carbon atom from the methyl end of the carbon chain (e.g., linoleic acid (LA) and
arachidonic acid (AA)) [134].
Both omega-3 and omega-6 PUFAs are precursors to potent lipid mediator signalling
molecules, termed “eicosanoids” with critical roles in the regulation of inflammation.
Omega-3 PUFAs are precursors to anti-inflammatory eicosanoids such as the 3-series
prostaglandins, thromboxane A3 (TXA3), and the 5-series leukotrienes (LTs), while omega-
6 PUFAs are precursors to proinflammatory eicosanoids such as the 2-series prostaglandins,
and thromboxanes (TXA2), and the 4-series of leukotrienes (LTB4) [135]. Depending on
their abundance in the diet, these PUFAs often compete with each other for binding to the
enzymes involved in eicosanoids formation including cyclooxygenase (COX) and lipoxy-
genase (LOX) [136]. Therefore, a diet rich in omega-6 PUFAs and low in omega-3 PUFAs
can elevate omega-6 to omega-3 ratio with a pro-inflammatory eicosanoid profile promot-
ing an inflammatory phenotype [137]. Further anti-inflammatory properties of omega-3
PUFAs include, negative regulation of the activity of enzymes involved in inflammatory
eicosanoids production such as COX-1 [138], the activation of the G-protein receptor, and
reducing the activation of NF-κB [138,139]. There are also reports of involvement of omega-
3 PUFAs in attenuating oxidative stress by reducing oxidative stress-induced DNA damage
in vascular endothelial cells, reducing intracellular ROS and increasing the mRNA levels of
antioxidant molecules, such as heme oxygenase-1, thioredoxin reductase-1, and superoxide
dismutase [140]. Supplementation with n-3 fatty acids has also been shown to reduce
plasma F2-isoprostanes levels [141].
In spite of some evidence regarding the antioxidant properties of omega-3 PUFAs,
it should be noted that both omega-3 and omega-6 PUFAs are chemically susceptible
to oxidation and are major sites of oxidative attack in vivo due to their relatively large
number of double bonds and the position of these bonds within their structure [142].
Oxidative modifications to omega-3 and omega-6 PUFAs result in the formation of lipid
oxidation products (LOPs), including 4-hydroxyhexenal (4-HHE), and 4-hydroxynonenal
(4-HNE), respectively [143]. Furthermore, oxidation of the omega-6 linoleic acids content
of LDL-C during oxidation processes produces potent pro-oxidants such as 9-hydroxy-
10,12-octadecadienoic acid (9-HODE) [144].
7.2.5. Dietary Glycaemic Index
Dietary glycaemic index (GI) is a ranking of various carbohydrates according to the
extent to which they raise plasma glucose levels after ingestion [145]. Consumption of
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foods with higher GI can contribute to either an acute or chronic elevation of plasma
glucose, i.e., hyperglycaemia, which plays a significant role in developing oxidative stress
and inflammation [146–148]. Hyperglycaemia induces oxidative stress and inflammatory
processes via several well-known mechanisms, including high generation of superoxide an-
ion by the mitochondria [149], glycation of antioxidant enzymes such as thioredoxin [150],
activation of the polyol pathway, reducing plasma levels of NAD+ [151], activation of
NF-κB [152], activation of protein kinase C [153], and increasing intracellular formation of
the pro-oxidants such as advanced glycation end products (AGE) [154].
Several studies have shown the positive association between dietary GI assessed
by a food frequency questionnaire during a 12-month period and plasma and urinary
lipid peroxidation biomarkers of MDA and isoprostanes in healthy cohorts [147]. In
healthy subjects after ingesting foods with different GI values, levels of the oxidative
stress biomarker nitro-tyrosine and the activation of pro-inflammatory gene NF-κB were
significantly higher in subjects in the high GI group compared to subjects in the low GI
group [146]. Studies in diabetic subjects have also shown the effect of meals with high GI
values on increasing plasma levels of MDA [151], CRP and TNF- α [155], and also raising
LDL-C susceptibility to oxidation, as well as reducing total radical-trapping antioxidant
parameter (TRAP) [151].
7.2.6. Fruits and Vegetables
As rich sources of various antioxidants and vitamins (e.g., vitamin C and E), and a
wide range of bioactive compounds known as phytochemicals (e.g., carotenoids), fruits
and vegetables have long been recognised for their antioxidant and anti-inflammatory
properties [156–158]. In this regard, several studies have shown the effects of high intakes
of fruit and vegetables on reducing levels of oxidative stress and inflammatory biomarkers
such as MDA [159], 8- isoprostane F2α [160], oxidised LDL-C [161], 8OHdG [162], CRP,
interleukin receptor 1 (ILR1), IL6, and TNF-α [163]. In addition, consumption of a variety
of fruits and vegetables has been reported to increase plasma and tissue levels of vitamin C
and E, and also carotenoids such as lutein, zeaxanthin, α-carotene, β -carotene and lycopene,
leading to a significant increase in plasma total antioxidant capacity (TAC) [164,165].
As lipid-soluble phytochemicals, carotenoids can also locate within biological mem-
branes, and consequently, play a critical role in protecting cellular membranes as well as
lipoproteins against damage by peroxyl free radicals [166,167]. It has also been shown that
the intake of lycopene-rich vegetable products can prevent lipid peroxidation as indicated
by decreased urinary F2-isoprostane and reduced LDL-C susceptibility to oxidation [168].
Furthermore, the intake of vitamins such as C and E from dietary sources including fruits,
vegetables, nuts and seeds is negatively associated with plasma levels of oxidative stress
biomarkers such as 8-isoprostane F2α and 8-oxo-7,8-dihydroguanine [169].
7.2.7. Nutrient-Poor Foods
It is now widely promoted that a combination of dietary components can be more
strongly associated with an inflammatory and oxidative stress profile than any single
component considered individually [28]. Hence, the role of foods with complex matrices
should also be taken into account in this context. Processed foods lacking nutrient density
such as fast foods and sugar-sweetened soft drinks can still have a multifarious matrix rich
in saturated and trans fatty acids, omega-6 PUFAs, sugar, and AGEs, which as mentioned
previously, can all trigger the inflammatory response with consequent oxidative stress and
cell damage [170]. In addition to increased oxidative damage regular consumption of these
nutrient-poor foods can also lead to deficiencies in major micronutrients such as vitamins
A, E, D, zinc and selenium which can weaken the body’s innate biochemical capability to
neutralise the generated free radicals [171].
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7.3. Common Social Drug Use
7.3.1. Alcohol Intake
Alcohol is mainly metabolised into acetaldehyde by alcohol dehydrogenase in the
liver [172]. However, it can also be metabolised by activation of the 2E1 isoform of the
cytochrome P450 (CYP2E1) oxidase system which is induced during chronic alcohol con-
sumption [173]. This process can lead to the generation of ROS and highly reactive free
radicals including hydroxyl radicals and superoxide anions [174]. Chronic alcohol intake
can cause hepatic accumulation of the hydroxyethyl radical and MDA, and deplete the
cellular antioxidant glutathione (GSH) levels in rats [175]. Further studies in animals
have revealed that high ethanol intake can increase liver 8-oxoguanine [176], and urinary
8-iso prostaglandin-F2α [177]. Studies in humans have shown that alcohol consumption
in heavy alcohol drinkers can increase plasma levels of oxidised LDL-C [178], advanced
glyoxidation end products (AGE) [179] and acetaldehyde-protein adducts, all of which are
potent oxidants [180]. While high intakes of alcohol are consistently linked to wide spread
tissue damage, a recent study by our group observed that chronic alcohol intakes equiva-
lent to only 1–2 standard drinks a day were associated with a reduction in levels of total
NAD(H), a recognised marker of intracellular metabolic and redox status, and an increase
in levels of the inflammatory cytokine IL-6 in human cerebrospinal fluid (CSF) [181].
7.3.2. Caffeine Intake
Caffeine (1,3,7-trimethylxanthine) is an alkaloid present in varying concentrations in
coffee, tea, colas, energy drinks and chocolate [182,183]. While crude caffeine extract has
been shown to possess limited lipophilic and hydrophilic antioxidant and cyclooxygenase-2
inhibitory activity, pure caffeine, appears to possess none of these attributes [184]. There is
evidence that caffeine ingestion can increase lipid oxidation [185], enhance exercise-induced
lipid peroxidation, indicated by plasma MDA and decrease plasma TAC levels in young
men [186]. Furthermore, prenatal exposure to caffeinated energy drinks has been shown to
induce oxidative stress and to increase lipid peroxidation in the liver, kidney and brain of
newborn mice [187]. Caffeine, in either low or high concentrations has been reported to
be significantly associated with a proinflammatory cytokine profile with elevated plasma
levels of TNF-α, CRP [188], IL-1β [189], IL- 6, serum amyloid-A (SAA) [188], and soluble
vascular cell adhesion molecule-1 (sVCAM-1) [190], and decreased serum levels of the
anti-inflammatory cytokine IL-10 [189]. It has been suggested that caffeine produces these
effects by inducing the expression of toll-like receptor 4 (TLR-4) and activating NF-κB
pathways that increase the expression of inflammatory molecules [191,192].
7.3.3. Cigarette Smoking
As a typical example of an oxidative stress-inducing compound, cigarette smoke
contains more than 4000 different chemicals including oxidants and free radicals, many of
which have established harmful effects [193]. Not surprisingly, cigarette smoking not only
delivers oxidants and free radicals to the body, but also induces pro-inflammatory signalling
via activation of NF-κB, which can exacerbate oxidative stress [194]. Not surprisingly
therefore, smoking has been shown to be associated with high plasma levels of oxidative
stress biomarkers such as oxidised LDL and isoprostane, and inflammatory biomarkers
such as IL-1β, IL-6, IL-8, hs-CRP and soluble adhesion molecules [195].
7.4. Physical Activity
Emerging evidence suggests that regular physical activity, especially endurance train-
ing, can elevate antioxidant and anti-inflammatory biomarkers levels in the vasculature,
the skeletal muscle and the circulation by various mechanisms [196,197]. Acute exercise
causes a transient increase in ROS levels, providing the required stimulus for activating
the antioxidant defence system. However, during chronic exercise this situation can be
compensated for by upregulating antioxidant enzymes and thus, reducing the impact of
free radicals production across the day [198]. In this context, several studies in animals
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and humans have shown that chronic exercise can increase serum total antioxidant status
(TAS) [199], and antioxidant enzymes such as glutathione peroxidase [200] and haem
oxygenase-1 (HO-1) [201] and reduce the levels of serum oxidative stress biomarkers, F2-
isoprostanes [202], and MDA [196]. Regular exercise has also been shown to be associated
with lower levels of several proinflammatory cytokines including interferon-γ (IFN-γ),
IL-1β [203], CRP [204], IL-6 [202], IL-1β and TNF-α, and higher levels of anti-inflammatory
molecules such as IL-4, IL-10, and transforming growth factor-β (TGF-β) [205].
7.5. Sleep and Tissue Oxygenation
It has been hypothesised that “good sleep” represents a state in which anti-oxidant po-
tential is increased thereby improving the removal of free radicals generated during waking
hours [206,207]. Experiments support the assertion that long-lasting wakefulness and sleep
deprivation are associated with elevated oxidative damage and inflammation [208,209].
Increased levels of lipid peroxidation biomarkers such as myeloperoxidase-modified LDL-
C [208], reduced levels of antioxidant enzymes such as glutathione peroxidase, catalase,
and superoxide dismutase [210], and elevated production of pro-inflammatory molecules
including IL-1β, IL-6, IL-17 [211] and high sensitivity C-reactive protein (hs-CRP) [212]
have been reported in several animal and human studies.
One of the most common sleep-related disorders that represent a key public health
problem is obstructive sleep apnoea (OSA). OSA is defined by repetitive episodes of
upper airway collapse during sleep resulting in nocturnal intermittent hypoxia with the
consequent induction of oxidative stress [213,214]. In this context, experiments in patients
with OSA have revealed excessive superoxide radical production from leukocytes [215] and
reduced bioavailability of nitric oxide (NO) the main endothelial-derived vasodilator linked
to oxidative stress [216]. Furthermore, increased serum concentrations of TBARs [217] and
exhaled breath 8-isoprostane [216], increased urinary 8-OHdG [218], and higher plasma
advanced oxidation protein products [219] have been reported. There is also evidence for
decreased plasma total antioxidant status (TAS), vitamin A and E [220], and reduced plasma
levels of antioxidant enzyme, superoxide dismutase [221], and paraoxonase-1 [217] in OSA.
Several studies have also suggested that the intermittent hypoxia in OSA can stimulate
inflammatory pathways [222]. In this context, OSA patients have shown increased plasma
levels of TNF-α, and IL-8 consistent with the extent of hypoxia during sleep [223].
7.6. Psychological Factors (Stress, Anxiety and Depression)
Mild anxiety is a normal response to psychological stress. However, when such
responses become extreme and persistent, it is considered pathologic and is referred to as
anxiety disorder (AnxD) [224]. AnxDs are implicated in a number of psychiatric disorders,
in particular depression [225]. It is well known that oxidative stress and inflammation
play a major role in both initiation and progression of these diseases [226,227]. Elevated
plasma levels of ROS [228,229] and oxidative stress biomarkers such as MDA [230], 8-
iso-prostaglandin F2 [231], and 8-OHdG [232] are important features of AnxD and major
depression. Furthermore, studies have also reported decreased plasma TAC [233], reduced
activity of antioxidant enzymes such as glyoxalase 1 (GLO1) [234] and reduced plasma
levels of antioxidants such as vitamin E [235], GSH [236] and coenzyme Q10 [237] in
these disorders.
Anxiety and depression are also accompanied by an increased inflammatory profile
as indicated by elevated serum levels of a variety of pro-inflammatory cytokines such
as IL-6 [231], TNF-α [233] and CRP [238]. There is also evidence for the induction of
inflammatory enzymes such as indoleamine 2,3-dioxygenase (IDO), a rate-limiting en-
zyme for the metabolism of tryptophan via the kynurenine pathway [239,240]. Increased
catabolism of tryptophan by IDO can lead to depletion of antioxidants like tryptophan
and its metabolite serotonin (5-hydroxy tryptophan), and also increased synthesis of the
pro-oxidant tryptophan catabolites (TRYCATs), quinolinic acid and kynurenine [241].
Antioxidants 2021, 10, 15 13 of 32
A model that develops from these observations suggests that unhealthy lifestyle
behaviours trigger increased oxidative activity (via several sources, including inflammation)
leading to an often-chronic state of redox imbalance (oxidative stress) that gradually shifts
the body’s biochemistry toward a diseased phenotype. If unhealthy lifestyle behaviours
persist, the resulting biochemical adaptation will, over a period of time, drive the body to a
state of disease [242–244] (Figure 3).
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8. Evidence that Changes in Lifestyle-Linked Oxidative Stress Is Detectable in
Disease-Free Humans
As mentioned, several studies have shown significant associations between either
individual lifestyle behaviours or composite lifestyle scores, and oxidative stress and
inflammatory biomarkers and risk of various NCDs such as CVDs [31,32,242,245–248].
However, though oxidative stress and inflammation have been demonstrated clearly in
the presence of disease, there are currently limited data showing a relationship between
lifestyle behaviours, subclinical changes in oxidative stress and inflammatory biomarkers
and changes in classic disease markers during the stage where no clinical symptoms
of disease are present. In other words, few studies have investigated whether changes
in oxidative stress and inflammatory biomarkers are observable in otherwise healthy
persons in which “unfavourable” lifestyle behaviours are nonetheless present. Even though
some authors have suggested the measurement of oxidative stress and inflammatory
biomarkers be included in routine analysis performed in clinical laboratories [249–254],
they were generally focused on disease management, and methodological aspects, rather
than disease prevention. In addition, they provided no link to lifestyle behaviours as the
main underlying cause of disease. Hence, additional work is required to further develop
the concept and identify the potential benefits of monitoring levels of oxidative stress
and inflammatory biomarkers both in terms of its value to early identification of NCD
pathologies and its link to multiple lifestyle behaviours in apparently healthy individuals.
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Among the few studies available in this context, results from our research group have
shown that lifestyle-associated changes in oxidative stress and/or inflammatory biomarkers
can indeed be detectable even in humans with no clinical symptoms of disease [255]. Thus,
indicating that changes in oxidative inflammatory activity may be present during the
prodromal or developmental phase of the disease process. In this study, we showed that a
simple measure of redox balance, the ratio of total antioxidant capacity to hydroperoxide
ratio (TAC/HPX ratio), was sensitive enough to be significantly associated with lifestyle
behaviours including body fat percentage, sleep quality, sleep apnoea, depression and
dietary intakes of red meat and caffeine, in healthy humans [255]. Lipid hydroperoxide
(HPX) has been shown to be a reasonably stable, ubiquitous and sensitive by-product
of lipid peroxidation [249,256,257]. Due to their propensity to contain double bonds,
membrane-associated lipids appear to be very vulnerable to free radical insults, and thus
biomarkers associated with lipid peroxidation have been shown to be more sensitive than
other markers such as protein oxidation products [258]. The coupling of HPX with a
measure of total antioxidant capacity (TAC), an integrated measure of all antioxidants
present in plasma [259], provides an index of the degree of ongoing free radical damage,
relative to available antioxidant resources, as it relates to the plasma. Thus, the TAC/HPX
ratio provided an added degree of sensitivity in detecting an otherwise healthy individual’s
specific changes in redox balance in response to their set of lifestyle challenges [255].
Importantly, these findings also showed that the plasma redox potential could have
clinical relevance as the TAC/HPX ratio was independently associated with NCD risk and
changes in classic CVD risk markers such as LDL-C, total cholesterol and fasting plasma glu-
cose (FPG) [255]. Similar relationships had been previously reported by Brunelli et al. (2017)
who showed that plasma antioxidant capacity was significantly associated with traditional
cardiovascular risk factors, including total cholesterol and total cholesterol to HDL-C ratio,
in a healthy population [260].
Using an otherwise healthy cohort, we also observed that the TAC/HPX ratio was
associated with the Framingham risk score (FRS), an established CVD risk predictor, which
was independent of the conventional CVD risk markers such as LDL-C, HDL-C and
blood pressure [255]. This association is consistent with earlier reports in which FRS was
associated with other serum oxidative stress-linked biomarkers such as peroxiredoxin [261],
γ-glutamyltransferase (GGT) [262], bilirubin [263], glutathione redox state [56], oxidised
disulphide cysteine [264], oxidised phospholipids [265], oxidised LDL [266], 9-hydroxy
eicosatetraenoic acids, and F2-isoprostanes [57]. Collectively, these data suggested that
changes in plasma redox balance, especially in the preclinical stage when the person is
assumed to be healthy, may reflect an individual’s early biochemical shift toward disease.
However, information from future longitudinal studies that include a comprehensive range
of inflammatory and oxidative markers will be needed to verify this hypothesis.
As previously outlined, lifestyle behaviours are recognised as major factors influenc-
ing the subclinical risk indicators of NCDs such as CVD changes in carotid intima-media
thickness (CIMT) in the general population [267–269]. The critical role of oxidative stress
and inflammatory processes in the development of vascular abnormalities and increased
CIMT has been established in several studies in clinical cohorts [18,270]. Interestingly, the
results from the same healthy cohort in our lab also showed that the collage of lifestyle
behaviours could link to increased risk of CIMT independent of conventional CVD risk
markers. In other words, changes in an integrated measure of lifestyle behaviours were
shown to be strongly associated with changes in CIMT and at the same time with plasma
biomarkers of redox balance and oxidative stress [271]. As this measure of lifestyle be-
haviours was also associated with oxidative stress processes in our cohort with no clinical
signs of disease, it can be inferred that oxidative stress may play an independent role in
the initiation of subclinical abnormalities involved in the development of CVD. Therefore,
relying on conventional biomarkers such as LDL-C to estimate the risk of disease without
considering the redox state might not be sensitive enough to identify the actual risk of
developing disease for individuals whose redox state is responding poorly to their constel-
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lation of lifestyle behaviours. These findings are consistent with results of other studies
that reported independent associations between oxidative stress and CIMT in disease-free
individuals [18,56].
9. Clinical Application of Monitoring Oxidative Stress and Inflammation
Collectively, current available evidence suggests that, oxidative stress and inflamma-
tory pathways represents a sensitive shared molecular pathway between various lifestyle
behaviours through which these behaviours may gradually drive an individual’s biochem-
istry/physiology toward a state of developing disease. Consistent with this hypothesis
there is a developing body of evidence showing that oxidative stress-associated changes
are detectable in apparently healthy individuals in association with specific lifestyle be-
haviours [255,271]. Thus, the measurement of biomarkers associated with oxidative stress
(and inflammation), may help with predicting early shifts toward the development of
NCDs and hence may enhance the ability to correctly characterise an individual’s disease
trajectory. Therefore, monitoring oxidative stress and inflammatory biomarkers and/or
including a measure of oxidative stress and inflammation in any risk assessment tool
may provide an early and more direct assessment of the presence of damage processes
that go beyond the conventional downstream risk factors currently used for predicting
disease risk. An appropriate clinical application of this concept is that it may provide an
early indication of whether an individual’s biochemistry is driving him/her toward health
or disease (Figure 4). On-time distinction of this trajectory can enable the initiation of
appropriate modifications (mainly lifestyle-related) and assist with a better health outcome
in terms of prevention of chronic NCDs.
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Figure 4. Assessment of redox state (i.e., assessment of the degree to which oxidative stress is present)
as a possible approach for early distinction of whether various lifestyle behaviours are driving
an individual toward health or toward development of disease-related pathologies. NCDs: non-
communicable diseases; TAC: total antioxidant capacity; HPX: lipid hydroperoxides; hc-CRP: high
sensitivity C-reactive protein; Chol: cholesterol; TG: triglycerides; HDL: high density lipoprotein.
This may have some enhanced discriminating capacity for those at risk of disease as
it will identify individuals whose biochemistry is not responding well to their collage of
lifestyle choices and therefore are in the process of developing an NCD. Assessing NCD
risk using (or at least including) oxidative stress and inflammatory markers is therefore
increasing the focus on upstream causative metabolic processes rather than the less specific
downstream risk factors such as body weight and lipid levels.
It is relevant to reiterate that a condition of oxidative stress and inflammation is not a
diseased state but is rather a preclinical state representing significant cellular stress and
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damage [18,56,264,272]. The information and perspective presented in this paper supports
the view that this state can be produced as a result of chronic exposure to various unhealthy
lifestyle behaviours. The damage caused by oxidative stress and inflammation, if not
detected early and prevented, can accumulate over time causing serious tissue remodelling
that will eventually result in a diseased phenotype [15,16,242]. Therefore, the assessment
of redox state during the early stage when no clinical symptoms of disease are manifest
can assist with identifying an individual’s early biochemical shifts toward development
of disease. In this way, the ongoing tissue damage due to chronic oxidative stress and
inflammation can be reduced or even halted by early modification strategies such as
lifestyle changes. This will prevent or limit development of irreversible organ damage and
subsequent disease. Improving the course of preclinical disease in this way not only can
provide improved patient outcomes but also can reverse disease progression and, therefore,
reduce both the need and costs of ongoing healthcare.
When fully developed, this approach may offer a way to bridge the gap between
the preventive aims of population-based public health strategies and the therapeutic
goals of patient-centred clinical practices to more favourably address individuals wellness
needs (Figure 5).
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10. Monitoring Oxidative Stress and Inflammation
As mentioned, our research group previously reported that different lifestyle be-
haviours are associated with changes to the oxidative stress biomarkers TAC/HPX which
were detectable in a human cohort with no clinical symptoms of disease [255]. In addition
we showed that changes in redox balance (based on lifestyle) correlated with the TAC/HPX
biomarkers and with changes in the CVD risk factor CIMT [271]. These observations are
consistent with the hypothesis that OS/inflammatory markers are early indicators of devel-
oping NCDs and if monitored, can enable effective treatment strategies in the preclinical
disease phase before irreparable tissue damage occurs.
Unfortunately, a clinically validated and universally accepted profile of oxidative
stress (and to some extent inflammatory) biomarkers has not yet been established in the
clinical context. However, a wide variety of biomarkers and analytical methods have
been developed to measure oxidative stress and inflammation in the research and clinical
arenas. While there are popular clinical markers of inflammation (e.g., hsCRP) clinically
validated markers of oxidative stress are still not apparent. As a general recommendation,
any analytical method for measuring OS and inflammation should be accurate, sensitive,
specific, reproducible, and interference-free [273]. Furthermore, to promote their use
in clinical settings, the methods should be based on a simple and quick protocol, and
involve low cost. Considering the highly reactive nature of oxidative species and their
short half-life, this is a formidable challenge and care needs to be taken to ensure the
stability of the sample to avoid artefactual oxidation. Suitable analytes must be able
to be stabilised in the clinical environment, present in quantifiable concentrations and
measurable within the detection range of a reliable analytical method across populations,
allowing the establishment of reference values. The analyte should also ideally be a specific
and major product of oxidative/nitrosative damage [273,274]. To our knowledge, no
individual oxidative stress biomarker meets all of these technical requirements. However,
some are better than others and a select panel of currently available markers will likely
provide the most clinically useful information [274]. While it is recognised that further
development in this area is needed, we have listed a selected range of biomarkers used for
detecting oxidative stress and inflammation that are adaptable to the clinical environment
(Tables 1 and 2) [252,275–289]. With careful selection of markers and consideration of
the points mentioned above, erroneous interpretations can be minimised and an accurate
profile of an individual’s biochemical redox health status should be obtainable and able to
be applied to the (pre)clinical setting.
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Table 1. Potential biomarkers of oxidative stress (OS).
OS Marker Advantages Disadvantages Reference
IsoPros
Can be detected in various samples
(serum, plasma urine) and has been
shown to be elevated in the presence
of a range of cardiovascular risk
factors and cancer
Evidence in clinical disease still




Easy to quantify in serum, plasma or
urine. Studies show MDA can predict
progression of coronary artery disease
and carotid atherosclerosis at 3 years.
TBARS assay is non-specific (can
detect aldehydes other than MDA)
therefore potential for interferences.
Test available in specialist labs only.
[252]
Hydroperoxides (HPX)
Lipid hydroperoxides are non-radical
intermediates of lipid peroxidation.
If frozen on collection, relatively
stable in serum/plasma and can be
transported. Growing body of
evidence for correlation with clinical
disease. Commercial test
kits available
Can undergo reductive degradation if




Human studies have demonstrated
association with coronary artery
disease independent of traditional
risk factors
Circulating levels not equivalent to
tissue levels. Current detection
methods are expensive and




Measured in serum or plasma.
Commercial assays available. Strong
evidence that MPO correlates with
cardiovascular disease risk
Influenced by sample storage and




Serum or plasma levels routinely
available as a clinical marker in many
larger routine pathology labs.
Elevated in coronary artery disease,
increasing oxLDL correlates with
increasing clinical severity. Also is
predictive of future coronary artery
disease in healthy population. Good
reproducibility from frozen samples
Ox LDL has been studied mostly in
relation to CVD so results not





Plasma levels considered a good
measure of the activity of the low
molecular weight, antioxidants,
including albumin, Vitamin C, SH
group containing antioxidants
(glutathione), polyphenolic and
carotenoid compounds and bilirubin.
Has been correlated to a variety of
disease states. Commercial testing
kits available
The specific contribution of
antioxidant enzymes such as catalase
and SOD are excluded
[280]
Gene expression
The change in expression of various
genes may reflect altered redox
balance and can be measured
simultaneously using
microarray technology
Expensive and It is unclear if
expression profiles of cells in
biological samples reflect that in
clinical tissues. Test only available
form specialist labs
[281]
Abbreviations: IsoPros (F2 Isoprostanes), MDA (malondialdehyde), HPX (hydroperoxide), MPO (myeloperoxiodase), oxLDL (oxidised low
density lipoprotein).
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Table 2. Potential biomarkers of inflammation.
Inflammation
Linked Marker Description/Advantage Disadvantages Reference
IL-6
Early release pro-inflammatory cytokine
produced in response to infections and
tissue injuries
Half life of 10 min. Therefore, only elevated
during active inflammatory activity. Can also
have anti-inflammatory effects.
Test only available in specialist labs
[282]
TNF-α Pro-inflammatory cytokine produced bymacrophages and lymphocytes
Half life of 18 min. Therefore, only elevated
during active inflammatory activity. Test
only available in specialist labs
[282]
IL-1β Pro-inflammatory cytokine andlymphocyte/monocyte activating factor
Half life of <4 h. Therefore, only elevated
during active inflammatory activity. Test
only available in specialist labs
[282]
IL-8 Pro-inflammatory cytokine produced bypolymorphonuclear (PMN) cells
Half life of ~4 h. Therefore, only elevated
during active inflammation due largely to
bacterial infections.
Test only available in specialist labs
[282]
IL-10, IL-4
Anti-inflammatory cytokines. IL-4 produced
by activated T cells, mast cells, basophils,
eosinophils, and Natural killer T cells.
IL-10 produced by macrophages, dendritic
cells (DC),3 B cells, and various subsets of
CD4+ and CD8+ T cells
Half life of <4.5 h. Therefore, only elevated
during active inflammatory activity. Test
only available in specialist labs
[282]
Fibrinogen
Pro-inflammatory regulation. High levels
well documented risk for many
inflammatory conditions. Test routinely
available in pathology labs
The mechanistic links between coagulation
and inflammation involving fibrinogen




Decreased in inflammation. Sensitive
indicator of inflammatory disease, in
particular kidney disease. Test available in
routine pathology labs
Ratio may change for reasons other than
inflammation, e.g., nutritional deficiencies
such as low protein intakes
[284,285]
Tryp/Kyn ratio
Sensitive indicator of T-helper 1 (i.e., IFN-γ)
immune responses. Reduced ratio reported
in a range of inflammatory associated
conditions including aging, cancer,
rheumatoid arthritis and CVD. Altered
Kyn:Tryp ratio remains longer and fluctuates
less than individual cytokines.
Test not routinely available outside of
research labs [286]
Neopterin
Macrophage activation product dependent
on IFN-γ activation. Levels remain elevated
for longer after IFN-γ levels return to normal.
Produced secondary to IFN-γ activation of




Acute phase protein produced by liver
following IL-6 activation. Widely used as a
clinical marker of inflammation. Levels
remain elevated longer than IL-6 and other
cytokines. Test widely available in routine
pathology labs.
As an acute phase protein levels rise by 2 h
peak by 48 h. Half life 18 h. However, one of






Large body of evidence linking reduced
omega-3 levels to conditions associated with
chronic inflammation including rheumatoid
arthritis, CAD and depression.
Indirect marker of inflammation potential.
Test only available in specialist labs [289]
Abbreviations: IL-6 (interleukin-6), TNF-α (tumour necrosis factor alpha), IL-1β (interleukin 1-bets), IL-8 (interleukin 8), IL-10, IL-4
(interleukin 10 and interleukin 4), Alb/Glob ratio (albumin:globulin ratio), Tryp/Kyn ratio (tryptophan:kynurnein ratio), hs-CRP (high
sensitivity C-Reactive protein), CVD (cardiovascular disease).
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11. Conclusions
Current literature supports the view that lifestyle-induced oxidative stress and in-
flammation are primary drivers of metabolic imbalances that cause NCDs. Oxidative
stress and inflammation produce a preclinical state of progressive tissue damage that, if
continued, will result in selected system failures and accompanying disease. Effective
management or prevention of the chronic subclinical tissue damage may be possible if
levels of the relevant oxidative stress and inflammatory biomarkers are quantified and
monitored and their link to an individual’s unique set of lifestyle behaviours are identified.
The construction of such a wellness assessment profile would serve as an early alarm for
the apparently healthy individual who is on a path to disease. This assessment of oxidative
and inflammatory markers could also provide a baseline from which the success of any
intervention can be monitored. Such a modified clinical approach has the potential to
improve the effectiveness of current public health strategies to both prevent and reverse
NCDs and their accompanying economic burden.
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